CJC-1295

Important naming distinction. "CJC-1295" strictly refers to the version with the Drug Affinity Complex (DAC) tail, the long-acting form. A related compound, Mod-GRF(1-29) (sometimes labelled "CJC-1295 without DAC"), shares the same modified GHRH backbone but lacks the albumin-binding tail, so it clears in about 30 minutes. Bodybuilding forums and vendors routinely use the names interchangeably. They are not the same molecule and they do not behave the same way.

For a peptide this popular, the human evidence is extraordinarily thin. The cornerstone is one peer-reviewed Phase I trial, Teichman et al. 2006 in JCEM, which showed CJC-1295 does what it was designed to do pharmacokinetically: bind albumin and produce a sustained rise in GH and IGF-1. A 2006 mouse paper and a 2006 follow-up Phase I analysis of GH pulsatility round out the original development programme. After that, the trail goes cold. ConjuChem ran an HIV lipodystrophy Phase II that was halted in 2006 following the death of a trial participant in Argentina; the attending physician judged the death (from coronary plaque rupture) most likely unrelated to the drug, but the programme never recovered and CJC-1295 was effectively abandoned. Nothing about real-world endpoints in athletes, dieters or anti-ageing users has ever been tested in a controlled human trial. Treat the marketing claims accordingly: extrapolation from PK data and animal studies, not clinical proof.

No safe or effective dose has been established because no approved human protocol exists. The original Teichman trial tested single subcutaneous doses of 60–250 µg/kg. Online communities describe milligram-range weekly injections, frequently combined with ipamorelin, but these regimens are not backed by clinical evidence and the purity of vials sold "for research use" is not regulated. A qualified clinician should be consulted before considering any peptide.

The safety profile in humans is essentially unknown. The Teichman Phase I trial reported headache, flushing, and injection-site reactions as the commonest dose-related adverse events. The class as a whole, GH secretagogues, is associated with reduced insulin sensitivity, raised blood glucose, and fluid retention at doses that meaningfully raise IGF-1, all of which are concerns for long-term, unsupervised use. There is also a well-recognised theoretical risk that sustained IGF-1 elevation could promote the growth of existing tumours; this has not been demonstrated for CJC-1295 specifically but is a standard caution across the GH/IGF-1 axis.

A single trial-participant death occurred during the 2006 ConjuChem lipodystrophy Phase II study; the attending physician's judgement was that the death (asymptomatic coronary disease with plaque rupture) was most likely unrelated to CJC-1295, but the study was halted and the programme was effectively abandoned shortly after. Online lore that has grown around this, including reports of unexplained deaths in users in subsequent years, is poorly documented and causation has not been established. We mention it because it is part of the public record, not because the link is proven.